Transition metal complexes of 6‐mercaptopurine: Characterization, Theoretical calculation, DNA‐Binding, molecular docking, and anticancer activity
Open Access
- 3 November 2020
- journal article
- research article
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 35 (1)
Abstract
6‐mercaptopurine (6‐MP) is used for treating various cancers and autoimmune disorders. A few examples of transition metal complexes of 6‐MP have been shown to enhance its anticancer activity, but many remain untested. We isolated five highly stable and colored metal complexes of 6‐MP and confirmed their structures by elemental analysis, spectral, and thermal techniques. Infrared (IR) spectra revealed that 6‐MP is a bidentate ligand that interacts through sulfur and pyrimidine nitrogen in a 1:2 (M:L) molar ratio. The magnetic susceptibility and electron paramagnetic resonance (EPR) spectra for the Cu(II) complex revealed an octahedral arrangement around the metal ion with strong covalent bonding. The fully optimized geometries of the metal structures obtained using density function theory (DFT)/B3LYP calculations were used to verify the structural and biological features. DNA titration revealed that the octahedral Cu(II) complex has a critical binding constant value ofKb= 8 × 105. Docking studies using three different cancer protein receptors were used to predict the biological applications of the synthesized drug‐metal complexes. Finally, cytotoxicity assays against a myeloma cancer cell line (MM) and a colon cancer cell line (Caco‐2) revealed favorable anticancer activity for the copper complex, exceeding that of the gold‐standard chemotherapeutic cisplatin.Keywords
This publication has 49 references indexed in Scilit:
- Nanotoxicity and Spectroscopy Studies of Silver Nanoparticle: Calf Thymus DNA and K562 as TargetsThe Journal of Physical Chemistry C, 2010
- Analytical detection and biological assay of antileukemic drug using gold nanoparticlesElectrochimica Acta, 2006
- The Determination of the Geometry of Cu(II) Complexes: An EPR Spectroscopy ExperimentJournal of Chemical Education, 2006
- DocetaxelDrugs, 2005
- New metal complexes of the antitumor drug 6-mercaptopurine. Syntheses and x-ray structural characterizations of dichloro(6-mercaptopurinium)copper(I), dichlorotetrakis(6-mercaptopurine)cadmium(II), and bis(6-mercaptopurinato)cadmium(II) dihydrateInorganic Chemistry, 1988
- Ruthenium(II)-6-mercaptopurine complex synthesis and solution properties. Molecular and crystal structure of bis(6-mercaptopurine)bis(triphenylphosphine)ruthenium(II) chlorideInorganic Chemistry, 1985
- Absorption and Circular Dichroism Studies of a Gold (I)-DNA ComplexJournal of Inorganic Biochemistry, 1984
- Stability, electronic spectra, and structure of the copper(II) chloride complexes in N,N-dimethylformamideInorganic Chemistry, 1980
- The crystal and molecular structure of 6-mercaptopurine monohydrate. A second, independent X-ray diffraction determinationActa Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 1969
- A Further Examination of the Molecular Weight and Size of Desoxypentose Nucleic AcidJournal of the American Chemical Society, 1954